DavidAWohlMD

Infectious Disease • Chapel Hill, NC

HIV/AIDS Medicine

Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Wohl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wohl's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-7198

Fax+1 984-974-4587

Education & Training

University of North Carolina HospitalsFellowship, Infectious Disease, 1994 - 1997
Duke University HospitalResidency, Internal Medicine, 1991 - 1994
Rutgers Robert Wood Johnson Medical SchoolClass of 1991

Certifications & Licensure

NC State Medical License 1994 - 2025

Clinical Trials

A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy
Completed
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
Completed
Phase 2
A Study of Patients With AIDS Syndrome
Completed
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV Start of enrollment: 2000 Aug 01
Completed
Phase 3
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
Completed
Phase 2
Botanical/Drug Interactions in HIV: Glucuronidation Start of enrollment: 2003 Sep 01
Completed
Phase 1
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination Start of enrollment: 2006 Mar 01
Completed
Phase 4
Raltegravir as Early Therapy in African-Americans Living With HIV Study Start of enrollment: 2008 Jun 01
Completed
Phase 1
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation Start of enrollment: 2011 Nov 01
Withdrawn
Phase 2
Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX Start of enrollment: 2012 Mar 01
Completed
Not Applicable
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera Start of enrollment: 2012 Oct 01
Completed
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
Completed
Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Modulation of Immune Activation by Aspirin Start of enrollment: 2014 Aug 01
Completed
Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
Completed
Phase 1, Phase 2
Biomarkers to Predict Time to Plasma HIV RNA Rebound Start of enrollment: 2017 Feb 23
Completed
PREPARE (A5361s) Substudy of REPRIEVE (A5332) Start of enrollment: 2017 Feb 28
Completed
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Start of enrollment: 2023 May 30
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

58 citations
All-Cause and Cause-Specific Mortality Among Black and White North Carolina State Prisoners, 1995–2005
David L. Rosen, David A. Wohl, Victor J. Schoenbach
Annals of Epidemiology. 2011-10-01
136 citations
All-cause and cause-specific mortality among men released from state prison, 1980-2005.
David L. Rosen, Victor J. Schoenbach, David A. Wohl
American Journal of Public Health. 2008-10-15
65 citations
Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort.
Essy Mozaffari, Aastha Chandak, Zhiji Zhang, Shuting Liang, Mark Thrun
Clinical Infectious Diseases. 2021-10-01

Press Mentions

Newsworthy from the School of Medicine, Week of August 16 – August 22August 21st, 2024
What's Behind COVID's Summer Comeback in North CarolinaAugust 14th, 2024
NC Is One of 27 States with ‘Very High’ COVID Activity, CDC Says. Time for New Vaccine?August 13th, 2024
Join now to see all

Grant Support

RCT Of An Augmented Test, Treat, Link, &Retain Model For NC And Texas PrisonersNational Institute On Drug Abuse2010–2011
Incarceration And Hiv-Infected InmatesNational Institute Of Mental Health2007–2010
Clinical Trial: Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine CNational Center For Research Resources2008
Clinical Trial: Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A522National Center For Research Resources2008
Clinical Trial: MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt TherapyNational Center For Research Resources2008
Clinical Trial: Enfurvitide (T-20) Intensification For Low Level Viremia (The LoNational Center For Research Resources2008
Clinical Trial: A5235 - Minocycline In The Treatment Of Hiv-Associated CognitiveNational Center For Research Resources2008
Long-Term Antiviral Management Of HCV And HIV-1 Coinfected Subjects (Slam-C)National Center For Research Resources2006–2008
Fat Redistribution And Metabolic Change In HIV InfectionNational Center For Research Resources2005–2008
Phase I/II Uridine Supplementation In HIV Lipoatrophy (Actg A5229)National Center For Research Resources2007
Phase 3 Comparison Of Lopinavir/Ritonavir Efavirenz Stavudine Lamivudine For IniNational Center For Research Resources2007
Enfurvitide (T-20) Intensification For Low Level Viremia (The Lola Study)National Center For Research Resources2007
Two Doses Of Gw433908/Ritonavir Given With Abacavir/Lamivudine ComboNational Center For Research Resources2006–2007
MRK AD5 HIV-1 GAG Vaccine In HIV-1 Subjects WHO Interupt TherapyNational Center For Research Resources2006–2007
Ezetimibe Therapy For Dyslipidemia In Patients Receiving HIV TherapyNational Center For Research Resources2006–2007
Nutriceuticals D-Glucarate, Silymarin And Piperine On PharmacokineticsNational Center For Research Resources2005–2007
Potent Combination Of Antiretroviral Regimen In African-American Men And WomenNational Center For Research Resources2004–2007
Phase II Once-Weekly Alendronate In Hiv-Infected Subjects With Decreased Bone DNational Center For Research Resources2004–2007
HIV+ Prison Releases To Access To HIV Care And ServicesNational Institute On Drug Abuse2003–2007
Combination Therapy With Fish Oil Supplement And FenofibrateNational Center For Research Resources2005–2006
Antiretroviral Switch At Lower VS Higher HIV-1 RNA Levels With RelapseNational Center For Research Resources2005–2006
Valganciclovir Pre-Emptive Therapy For CMV Viremia (Actg A5030)National Center For Research Resources2004–2006
ACTG A5142National Center For Research Resources2004–2006
Potent Combo Antiretroviral Regimen In AA Men And WomenNational Center For Research Resources2005
Fish Oil Supplementation PLUS Diet And Excercise VS Diet And Exercise Alone-HivNational Center For Research Resources2005
Metformin And Rosiglitazone Alone Or In Combination In Hiv-Infected SubjectsNational Center For Research Resources2004–2005
Immune Response To Pneumococcal Vaccine In Patients With HIVNational Center For Research Resources2004–2005
Fish Oil Supplementation PLUS Diet And Excercise Vs. Diet And Exercise Alone-HivNational Center For Research Resources2004
Combinations Of Potent Antiretroviral Therapy, Hiv-Specific ImmunizationsNational Center For Research Resources2004
Antiretroviral Switch At Lower Vs. Higher HIV-1 RNA Levels With RelapseNational Center For Research Resources2004
Thalidomide For Treatment Of Recurrent Aphthous Ulcers In HIVNational Center For Research Resources1999–2002
NCI AIDS Related Cancer Cohort Study (ACCS)National Center For Research Resources1999–2002
Ganciclovir Cidofovir CMV Retinitis TrialNational Center For Research Resources1999–2002
ACTG 379 Discontinuing Maintenance Therapy For CMV RetinitisNational Center For Research Resources1999–2002
HIV And CMV Viral Burden And Development Of CMV End-Organ DiseaseNational Center For Research Resources1998–2002
A Longitudinal Study Of The Predictive Value Of Quantitative CMVNational Center For Research Resources1997–2002
Trial Of Salvage Antiretroviral Therapies For HIV PTSNational Center For Research Resources2000
The Longitudinal Study Of Ocular Complications Of AIDSNational Center For Research Resources2000
Thalidomide For Recurrent Aphthous Stomatitis In HIVNational Center For Research Resources2000
HIV &Cmv &Development Of CMV End-Organ DiseaseNational Center For Research Resources2000
Ddl/D4t/Hu VS Ddl/D4t/Efv VS Protease Inhibitor In HIV PTSNational Center For Research Resources2000
Abt378/Ritonavir W/ Reverse Transcriptase Inhibitors In HIVNational Center For Research Resources2000
A Longitudinal Study Of Quantitative CMV In Pys W/ AIDSNational Center For Research Resources2000
Investigational New Drug Application For HIVNational Center For Research Resources1998–1999